From Bench to Bedside: Ensuring Adoption of Clinical Biomarkers

• Understanding drivers and barriers for the adoption of biomarkers 
• Sharing J&Js approach to market shaping through agility and partnerships 
• Future perspectives on how to manage adoption in the evolving landscape and new CDx modalities, such as AI

Speakers:

Marek Zurawski

EMEA Portfolio & Alliance Lead - Precision Medicine

Johnson & Johnson Innovative Medicine